Published in Blood on February 01, 1984
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest (1991) 1.38
Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis (2005) 1.24
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer (1985) 1.15
Bulky extramedullary plasmacytomata: rare mode of relapse in myelomatosis. J Clin Pathol (1989) 0.91
Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum. J Clin Pathol (1991) 0.83
Prognostic factors and classification in multiple myeloma. Br J Cancer (1989) 0.83
Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a biomarker for symptomatic multiple myeloma. PLoS One (2015) 0.79
Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma. J Korean Med Sci (2006) 0.77
The treatment of multiple myeloma--an important MRC trial. Br J Cancer (1994) 0.76
Urinary pseudouridine excretion in myelomatosis. Br J Cancer (1985) 0.75
Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma. PLoS One (2015) 0.75
Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol (2017) 0.75
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer (1981) 2.23
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 2.07
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res (1993) 1.98
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Endocarditis associated with ANCA. Clin Exp Rheumatol (1994) 1.85
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat (2001) 1.80
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 1.67
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer (2001) 1.66
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood (1999) 1.65
IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. Eur J Immunol (1999) 1.64
Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum (1993) 1.63
Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood (2001) 1.62
Inflammatory joint disease after immunizations. A report of two cases. Rev Rhum Engl Ed (1997) 1.61
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol (1989) 1.60
P53 deletion is not a frequent event in multiple myeloma. Br J Haematol (1999) 1.57
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum (1990) 1.51
Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum (2002) 1.48
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol (1993) 1.47
Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol (1995) 1.46
Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol (1998) 1.45
Polymorphism of the HLA-DMA and DMB genes in rheumatoid arthritis. Arthritis Rheum (1997) 1.44
Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. J Rheumatol (1997) 1.43
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis (2006) 1.42
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol (1999) 1.42
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest (1991) 1.38
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood (1994) 1.37
Immunogold localization of beta-1,3-glucanases in two plants infected by vascular wilt fungi. Plant Cell (1989) 1.35
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Aberrant recombination events in B cell lines derived from a kappa-deficient human. Nucleic Acids Res (1985) 1.33
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum (1990) 1.32
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol (1998) 1.29
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis (2013) 1.27
Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol (1999) 1.27
The AIMS2-SF: a short form of the Arthritis Impact Measurement Scales 2. French Quality of Life in Rheumatology Group. Arthritis Rheum (1997) 1.26
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis (2004) 1.25
Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol (1999) 1.25
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. Am J Med (1987) 1.23
Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis (1996) 1.23
Acute osteoporotic vertebral collapse: open study on percutaneous injection of acrylic surgical cement in 20 patients. AJR Am J Roentgenol (1999) 1.23
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res (1999) 1.23
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med (1994) 1.22
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia (1998) 1.22
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 1.21
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 1.20
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers (2000) 1.20
Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood (1997) 1.19
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol (1999) 1.19
HL-A antigens in rheumatoid arthritis. Vox Sang (1972) 1.17
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol (1992) 1.17
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood (1999) 1.16
Widespread use of serological tests for tuberculosis: data from 22 high-burden countries. Eur Respir J (2012) 1.15
Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.14
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.14
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer (1998) 1.13
The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw (2000) 1.12
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am (1992) 1.12
Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res (1995) 1.10
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood (1996) 1.10
Several thaumatin-like proteins bind to beta-1,3-glucans. Plant Physiol (1998) 1.10
Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol (2000) 1.10
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res (1998) 1.09
Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis (1997) 1.09
Significant impact of survivin on myeloma cell growth. Leukemia (2007) 1.08
Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer (1990) 1.07
Investigation of the HLA component involved in rheumatoid arthritis (RA) by using the marker association-segregation chi-square (MASC) method: rejection of the unifying-shared-epitope hypothesis. Am J Hum Genet (1993) 1.07
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells. Mol Cell Endocrinol (2001) 1.07
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol (2000) 1.07
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood (1995) 1.06
Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. J Rheumatol (1988) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06